Vanda, an American biotechnology company, has announced that its treatment imsidolimab has been granted orphan drug designation by the European Medicines Agency (EMA) for the management of generalised pustular psoriasis (GPP). This designation will enable a faster and more streamlined regulatory review process for the therapy, which targets the underlying causes of the condition.
Vanda's Imvidi Gets EU Orphan Drug Status for Generalised Pustular Psoriasis
UKPulse Health DeskPharmaceutical company Vanda has secured orphan drug designation from the European Medicines Agency (EMA) for its treatment imsidolimab in the management of generalised pustular psoriasis (GPP). The new status will facilitate faster review and approval processes for the therapy.
- Vanda's imsidolimab gains orphan drug status for GPP treatment
- EMA designation eases regulatory pathway for the therapy
- Implications for UK patients with GPP and the NHS
Why this matters: The news is significant for UK patients suffering from GPP, as it may lead to quicker access to the treatment, potentially improving their quality of life.
What this means for you: What this means for you: Patients with GPP in the UK may have faster access to this innovative treatment, offering new hope for managing their condition.